off-label drug use

AstraZeneca agreed to pay $3.1 million to settle a New York State Attorney General's lawsuit saying the British pharmaceutical company improperly promoted and marketed the schizophrenia drug Seroquel, concealing dangerous side effects such as diabetes from health care providers and the public. New...

A judge has finalized Allergan's $600 million settlement over the misleading marketing of its wrinkle-smoothing Botox medication. The pharmaceutical firm plead guilty to misbranding the product.

You know better than to believe everything companies say in ads, but when it comes to claims about the healthfulness of foods and other products, the untruths can reach outrageous levels. The question is: What can a government limited by the First Amendment do to stop them?

Pharmaceutical firm Allergan has settled criminal and civil charges that it promoted Botox for uses the FDA hadn't approved, agreeing to pay $600 million and enter into a "corporate integrity agreement." Allergan also dropped its related First Amendment lawsuit against the FDA.

A leading manufacturer of artificial hips and knees agreed to pay the state of Massachusetts $1.35 million to resolve allegations that it marketed orthopedic devices without regulatory approval and, to boost sales, withheld patient safety information from health care providers. A complaint filed...

One of the world's largest drug companies, AstraZeneca, agreed to pay $520 million to settle a U.S. government lawsuit claiming the company encouraged doctors to prescribe an anti-psychotic drug to children, veterans and the elderly outside its intended use. Seroquel is approved by the U.S. Food...